Optical Coherence Tomography for Assessment of the Treatment Effect of Tiotropium in Early Stage of COPD
Status:
Unknown status
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
The study aims to explore the reversibility of airway remodeling by Endobronchial Optical
Coherence Tomography (EB-OCT). In this study, EB-OCT is used to assess the treatment effect
of Tiotropium in early stage of COPD. Investigators recruit COPD patients in Grade A and
Grade C according to GOLD 2019. Patients in Grade A will begin to use Tiotropium once daily,
and EB-OCT, pulmonary function test and chest CT will be performed in baseline, 6 months, 1
year and 2 year. Patients in Grade C will begin to use LABA+LAMA (including but not limited
to Olodaterol / Tiotropium) or LAMA (Tiotropium) , same testing will be performed as patients
in Grade A. Primary endpoint is airway parameters accessed by EB-OCT. And secondary end
points are FEV1 and CT accessed pulmonary emphysema.